InvestorsHub Logo
Followers 13
Posts 1210
Boards Moderated 0
Alias Born 03/28/2010

Re: None

Wednesday, 11/15/2017 3:14:30 PM

Wednesday, November 15, 2017 3:14:30 PM

Post# of 1665
TheNewswire)

TheNewswire / Hamilton, ON, November 14, 2017

CTT Pharmaceuticals Holdings, Inc., an innovative life sciences company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes and experiences, today would like to provide a corporate update.

2017 YTD Achievements and Anticipated Goals

- CanniMed Therapeutics, our exclusive Canadian licensee in the Medical Cannabis industry has submitted it's application to Health Canada in regards to our proprietary sub-lingual wafer.

- US Patent and Trademark Office has issued US Patent # 14921501. This brings our patent portfolio to 4 issued patents, 2 pending and a PCT.

- Annual Report for 2016 has just been submitted to the OTC Markets and the 3 quarters of 2017 are currently being prepared and will be filed shortly.

- Currently in discussions with potential joint-venture partners and Pharmaceutical companies to license and commercialize various applications of it's Oral Thin Film Wafer.

"We expect to be formalizing our agreements with our potential joint-venture partners shortly" said Dr Pankaj Modi, CEO of CTT Pharmaceuticals, " In addition we are moving forward with our exclusive Canadian licensee CanniMed Therapeutics in obtaining Health Canada's approval for our Oral Thin Film Wafer"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTTH News